Fibroblast growth factor 19 is an independent prognostic parameter for hepatocellular carcinoma recurrence
Sweed, D., Kilany, S., Taha, M., Sweed, E., Abdelsattar, S., Mosbeh, A. (2021). Fibroblast growth factor 19 is an independent prognostic parameter for hepatocellular carcinoma recurrence. EKB Journal Management System, 5(4), 25-37. doi: 10.21608/jcbr.2021.73946.1206
Dina Sweed; Shimaa Kilany; Mohammad Taha; Eman Sweed; Shimaa Abdelsattar; Asmaa Mosbeh. "Fibroblast growth factor 19 is an independent prognostic parameter for hepatocellular carcinoma recurrence". EKB Journal Management System, 5, 4, 2021, 25-37. doi: 10.21608/jcbr.2021.73946.1206
Sweed, D., Kilany, S., Taha, M., Sweed, E., Abdelsattar, S., Mosbeh, A. (2021). 'Fibroblast growth factor 19 is an independent prognostic parameter for hepatocellular carcinoma recurrence', EKB Journal Management System, 5(4), pp. 25-37. doi: 10.21608/jcbr.2021.73946.1206
Sweed, D., Kilany, S., Taha, M., Sweed, E., Abdelsattar, S., Mosbeh, A. Fibroblast growth factor 19 is an independent prognostic parameter for hepatocellular carcinoma recurrence. EKB Journal Management System, 2021; 5(4): 25-37. doi: 10.21608/jcbr.2021.73946.1206

Fibroblast growth factor 19 is an independent prognostic parameter for hepatocellular carcinoma recurrence

Egyptian Journal of Cancer and Biomedical Research
Article 3, Volume 5, Issue 4, December 2021, Page 25-37  XML PDF (15.78 MB)
Document Type: Original Article
DOI: 10.21608/jcbr.2021.73946.1206
View on SCiNiTO View on SCiNiTO
Authors
Dina Sweedorcid 1; Shimaa Kilany2; Mohammad Taha3; Eman Sweedorcid 4; Shimaa Abdelsattar5; Asmaa Mosbeh email orcid 1
1Pathology Department, National Liver Institute, Menoufia University, Egypt
2Hepatology and Gastroenterology Department, National Liver Institute, Menoufia University, Egypt
3Hepatopancreatobiliary Surgery Department, National Liver Institute, Menoufia University, Egypt
4Clinical Pharmacology Department, Faculty of Medicine, Menoufia University, Egypt
5Clinical Biochemistry, and Molecular Diagnostics Department, National Liver Institute, Egypt
Abstract
Background: Hepatocellular carcinoma (HCC) remains a common cancer associated with a high mortality rate. Genes that drive HCC development accumulate randomly that could be a target for therapeutic management. In large-scale studies, the dysregulation of fibroblast growth factors (FGFRs) was detected in over 7% of cancers and served as an oncogenic signalling pathway. Amplification of FGF19 was found to be associated with the development of HBV and NAFLD related HCC with an ongoing clinical trial for targeting this pathway. Aim: We aimed to study FGF19 in HCV related HCC and to compare its expression within the two main morphological patterns. Material and Methods: This was a retrospective, case-control study that included 76 HCC cases and 53 adjacent non-tumour liver, 20 cirrhosis and 20 normal liver tissue as normal control. The Immunohistochemical expression turned into assessed in the studied groups. Results: FGF19 was expressed in 26.3% of HCC cases with no significant difference in its expression between two HCC subgroups (P=0.073). The expression of FGF19 was not differed in the HCC group according to the aetiology (P=0.605), prior HCV treatment (P=0.912) or background liver cirrhosis (P=0.931). The only factor increased FGF19 expression with the marked inflammatory activity of the background liver (P=0.026). COX regression analysis revealed that FGF19 was the single independent factor affecting tumour recurrence (P=0.04). Conclusions: FGF19 is commonly expressed in HCC cases independent from the etiological, background liver or morphological subtypes. FGF19 could be used as an indicator to predict tumour recurrence.
Keywords
FGF19; HCC; Macrotrabecular massive; NOS; Recurrence
Statistics
Article View: 405
PDF Download: 307